<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">TAKEDA, HIROYUKI</style></author><author><style face="normal" font="default" size="100%">OKADA, MASASHI</style></author><author><style face="normal" font="default" size="100%">SUZUKI, SHUHEI</style></author><author><style face="normal" font="default" size="100%">KURAMOTO, KENTA</style></author><author><style face="normal" font="default" size="100%">SAKAKI, HIROTSUGU</style></author><author><style face="normal" font="default" size="100%">WATARAI, HIKARU</style></author><author><style face="normal" font="default" size="100%">SANOMACHI, TOMOMI</style></author><author><style face="normal" font="default" size="100%">SEINO, SHIZUKA</style></author><author><style face="normal" font="default" size="100%">YOSHIOKA, TAKASHI</style></author><author><style face="normal" font="default" size="100%">KITANAKA, CHIFUMI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6311-6318</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><issue><style face="normal" font="default" size="100%">12</style></issue><abstract><style  face="normal" font="default" size="100%">Background: Targeting pathways regulating survivin expression, which has been implicated in multidrug resistance of cancer cells, is a promising strategy to overcome cancer chemoresistance. To date, the role of rho-associated protein kinases (ROCKs) in survivin expression remains largely unknown. Materials and Methods: The effects of ROCK inhibitors Y-27632 and fasudil on survivin expression and cell viability were determined by immunoblot analysis and dye exclusion, respectively, in PANC-1 CSLC, a cancer stem cell line derived from a serum-cultured, gemcitabine-sensitive pancreatic cancer cell line, PANC-1. Results: siRNA-mediated knockdown of survivin revealed that the gemcitabine resistance of PANC-1 CSLC was dependent on survivin expression. Both Y-27632 and fasudil, reduced survivin expression in PANC-1 CSLC cells and sensitized them to gemcitabine. ROCK inhibition also reduced survivin expression in various other human cancer cell lines. Conclusion: Small molecule inhibitor-mediated targeting of ROCK may be a viable strategy to overcome cancer chemoresistance through down-regulation of survivin.</style></abstract></record></records></xml>